{
    "nct_id": "NCT04552288",
    "official_title": "Phase II Study of IL-5-receptor-alpha-chain (IL-5Rα) Inhibition With Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients",
    "inclusion_criteria": "* Patients must have pathologically or cytologically confirmed solid or hematologic cancers.\n\nOR\n\n* Patient is receiving alpelisib for PIK3CA-Related Overgrowth Spectrum disorder.\n* Female and male aged 18 to 85 years, inclusively, at the time of Week 0/Day 1 of treatment.\n* Patients must have a therapy-related CTCAE grade 2/3 (See Appendix A)cutaneous adverse event defined as any cutaneous reaction listed below and blood eosinophil counts of at least .3 K/mcl.\n\n  * Rash maculo-papular\n  * Bullous dermatitis\n  * Pruritus\n  * Urticaria\n  * Eczema\n* Patients must plan to continue on culprit drugs (cancer patients).\n* Patients planning to receive alpelisib indicated for PIK3CA-Related Overgrowth\n\nSpectrum disorder OR patients receiving immunotherapy and/or targeted therapy, including but not limited to the following agents, will be eligible for inclusion:\n\n* Immunotherapies: ipilimumab, nivolumab, pembrolizumab, avelumab, durvalumab, atezolizumab tremelimumab.\n* Targeted therapies: trastuzumab, pertuzumab, alpelisib, osimertinib, everolimus, temsirolimus, sorafenib, regorafenib.\n\n  * Patients using topicals/orals for indication of skin rash/pruritus for at least 7 days should continue using these drugs for the study duration\n  * Adequate bone marrow, liver and renal function:\n* Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver involvement of their cancer)\n* Serum creatinine ≤ 1.8 xULN or calculated creatinine clearance >45 ml/min\n* Platelet count > 50 K/mcL , hemoglobin (Hb) > 8 g/dL, absolute neutrophil count (ANC) >1.0 K/mcL. Blood transfusion to meet the inclusion criteria will not be allowed.\n\n  * ECOG performance status 0-1 (see Appendix C).\n  * Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.\n  * Female patients are authorized to participate if they meet the following criteria:\n* Women of child bearing potential must meet both of the following conditions:\n* Have a negative serum pregnancy test prior to enrollment and within 14 days prior to administration of the investigational product (IP).\n* Patient must use an effective form of birth control (confirmed by the Investigator) throughout the study duration and within 16 weeks after last dose of IP.\n* Female subjects who cannot bear children as evidenced by one or more of the following:\n* Bilateral Oophorectomy\n* Bilateral Salpingectomy\n* Bilateral Salpingectomy-Oophorectomy\n* Hysterectomy\n* Menopause (no menses ≥ 1 year prior to treatment)\n* Surgical Sterilization (i.e., tubal ligation or blockage) Note: If criteria not met, patient should be regarded as having child bearing potential\n\n  * Subject must be able to receive a subcutaneous injection.\n  * New/worsening ercAE within 90 days prior to study enrollment. Note: This assessment will be performed by the treating investigator.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 85 Years",
    "exclusion_criteria": "* Concurrent use of another investigational drug or device for the ercAE (i.e., outside of study treatment) during, or within 4 weeks of treatment.\n* Patients receiving prednisone ≥ 20mg a day.\n* Known use of anti-IL-5 agents or biologics for the treatment of asthma which are known to decrease blood eosinophil levels.\n* Patients cannot use new topicals or medications for indication of pruritus or skin rash\n* Known history of anaphylaxis to biologic therapy.\n* A helminthic parasitic infection diagnosed within 24 weeks prior to the first treatment, that had not been treated with, or has failed to respond to, standard of care therapy.\n* Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.\n* Active infection that would impair the ability of the patient to receive study treatment.\n* Women who are pregnant or breast-feeding.\n* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.\n* Receipt of live attenuated vaccines 30 days prior to the date of randomization\n\n  ° Receipt of inactive/killed vaccinations (e.g., inactive influenza) is allowed provided they were not administered within 1 week before/after any investigational product administration.\n* Known history of allergy or reaction to the investigational product formulation",
    "miscellaneous_criteria": ""
}